Hypolipidemic drugs and diabetes mellitus


Authors: V. Bláha;  E. Mistrík
Authors‘ workplace: Klinika gerontologická a metabolická Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
Published in: Vnitř Lék 2009; 55(4): 357-362
Category:

Overview

Diabetes mellitus associates with high cardiovascular risk. The absolute values of cardiovascular risk tend to be even higher than as calculated from the SCORE tables. Recent randomized clinical trials have shown evidence of benefit and safety of more intensive LDL‑cholesterol lowering in patients with diabetes and established cardiovascular disease supporting guidelines for a more intensive LDL goal of therapy. A recent meta‑analysis has confirmed benefit on major coronary events and ischaemic stroke in many diabetic patient subgroups, including those with type 1 disease. The pathological combination of several lipoprotein metabolism abnormalities and the need to reach lipoprotein goals need combination therapy of hypolipidemic drugs with different mechanisms of action. Despite statin treatment, cardiovascular disease residual risk remains high. After LDL the next lipoprotein goal is to increase HDL. Although there has been disappointment with the first cholesteryl-ester-transfer-protein‑inhibitor, there is encouraging evidence that increasing HDL with the peroxisome-proliferator‑activator-receptor (PPAR)γ agonist, pioglitazone and nicotinic acid derivatives may contribute beyond statin therapy.

Key words:
diabetes mellitus type 2 – dyslipidaemia – hypolipidemic treatment – cardiovascular risk – atherosclerosis


Sources

1. Cubbon RM, Wheatcroft SB, Grant PJ et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995–2003. Eur Heart J 2007; 28: 540–545.

2. Ryden L, Standl E, Bartnik M et al. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology and of the European Association for the Study of Diabetes. Guidelines on diabetes, prediabetes and cardiovascular diseases. Eur Heart J 2007; 9 (Suppl C): C3–C74.

3. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800–1809.

4. Collins R, Armitage J, Parish S et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005–2016.

5. Bláha V, Andrýs C, Šmahelová A et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: Relationship to cholesterol turnover. Pharmacol Res 2006; 54: 421–428.

6. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta‑analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.

7. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below recommended levels in patients with diabetes and coronary heart disease: the Treating to New Targets (TNT) Study. Diabetes Care 2006; 29: 1220–1226.

8. Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448–1454.

9. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–732.

10. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.

11. Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48: 2482–2485.

12. Neil HA, DeMicco DA, Luo D et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29: 2378–2384.

13. Kearney PM, Blackwell L, Collins R et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of satins: a meta‑analysis. Lancet 2008; 371: 117–125.

14. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–1790.

15. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707–714.

16. Gordon DJ, Probstfield JL, Garrison RJ et al. High‑density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.

17. Barter P, Gotto AM, LaRosa JC et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357: 1301–1310.

18. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein‑C lowering and high‑density lipoprotein‑C elevation for optimum cardiovascular disease prevention with various drug classes and their combinations: a meta‑analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17: 631–636.

19. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high‑density lipoprotein cholesterol and regression of coronary atherosclerosis. JAMA 2007; 297: 499–508.

20. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505–1515.

21. Barter PJ, Caulfield M, Eriksson M et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.

22. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007; 356: 1364–1366.

23. Van der Steeg WA, Holme I, Boekholdt M et al. High‑density lipoprotein cholesterol, high‑density lipoprotein particle size and apolipoprotein A-1: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 634–642.

24. Betteridge DJ, Vergès B. Long‑term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005; 48: 2477–2481.

25. Dormandy JA, Charbonnel B, Eckland DJ et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279–1289.

26. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimpiride on carotid intima-medial thickness in type 2 diabetes; a randomized trial. JAMA 2006; 296: 2572–2581.

27. Nissen SE, Nicholls SJ, Wolski K et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561–1573.

28. Davidson M, Meyer PM, Haffner S et al. Increased high‑density lipoprotein cholesterol predicts the pioglitazone-medicted reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 2123–2130.

29. McCormack PL, Keating GM. Prolon­ged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65: 2719–2740.

30. Paolini JF, Mithchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid‑induced flushing in patients with dyslipidaemia. Am J Cardiol 2008; 101: 625–630.

31. Gordon DJ, Probstfield JL, Garrison RJ et al. High‑density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.

32. Nordestgaard BG, Benn M, Schnohr P et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.

33. Buse JB, Bigger JT, Byington RP et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i–33i.

34. Keech A, Simes RJ, Barter P et al. FIELD study investigators. Effects of long‑term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 4

2009 Issue 4

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account